Recently, Bayer announced that China’s National Medical Products Administration (NMPA) has approved the novel targeted drug sevabertinib for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who harbor HER2 (ERBB2) activating mutations and have experienced disease progression after at least one prior systemic therapy.
This means that no matter which country you are from, you can now access this globally advanced precision therapy through the Beijing South Region Oncology Hospital International Department.
Sevabertinib: Precisely Targeting HER2 Mutations
Sevabertinib is a novel, oral, reversible small-molecule tyrosine kinase inhibitor. It potently inhibits mutant HER2 (including HER2 exon 20 insertions and point mutations) as well as EGFR. Compared with traditional irreversible TKIs, a reversible TKI provides temporary, precise blockade of the target, enabling more controlled treatment and potentially reducing long-term side effects.
Encouraging Clinical Data: Significant Responses, Durable Benefits
The approval of sevabertinib is based on positive results from the international multicenter Phase I/II SOHO-01 trial:
- In patients who had not previously received HER2-targeted ADC therapy
The objective response rate (ORR) reached 64%, including 2.5% complete responses and 62% partial responses. The median duration of response was 9.2 months.
- In patients who had previously received HER2-targeted ADC therapy
The ORR was still 38%, including 5.5% complete responses and 33% partial responses. The median duration of response was 7 months.
The safety profile is manageable and consistent with previous reports, providing a reliable foundation for long-term treatment.
Why Choose Beijing South Region Oncology Hospital International Department?
As an international medical center focused on precision cancer care, we offer global patients:
- Multilingual medical team: Services in Chinese, English, Russian, Arabic, and more, ensuring seamless communication throughout.
- One-stop international patient services: Dedicated coordination from remote consultations and medical visa assistance to airport transfers, hospitalization arrangements, and post-treatment follow-up.
- Personalized treatment plans: Tailored targeted therapy and comprehensive management plans based on the patient’s genetic profile and overall condition.
Contact Us Today to Begin Your Journey of Hope
Beijing South Region Oncology Hospital International Department
Global Patient Hotline: 400-880-3716
WeChat: 17801183037
Email:
- 100085_010@163.com
- myimmnet@163.com
—
Your Life Deserves the Best Treatment
Whether you are seeking a first line of hope or have already progressed after multiple prior regimens, sevabertinib may offer an unprecedented turning point. The Beijing South Region Oncology Hospital International Department is ready to open a green lane for you—call 400-880-3716 now, or contact us via WeChat or email. Let us help you connect with leading experts, assess eligibility, and plan your treatment journey in China.
Don’t wait. Every call could be a new beginning.
Beijing South Region Oncology Hospital International Department — Bridging Global Patients with China’s Precision Medicine.
Post time: Apr-16-2026